Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
0.9200
+0.0049 (0.54%)
Oct 27, 2026, 4:00 PM EDT - Market closed
Allarity Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 0.35 | 0.32 | - | - | - | - |
| 0.35 | 0.32 | - | - | - | - | |
Revenue Growth | - | - | - | - | - | - |
Gross Profit | 0.35 | 0.32 | - | - | - | - |
Selling, General & Admin | 5.62 | 6.32 | 11.44 | 10.03 | 9.96 | 12.36 |
Research & Development | 6.35 | 7.43 | 6.89 | 7.9 | 7.64 | 14.2 |
Other Operating Expenses | -0.83 | -0.83 | -0.8 | -0.8 | -0.71 | - |
Operating Expenses | 11.14 | 12.93 | 17.54 | 17.13 | 16.89 | 26.56 |
Operating Income | -10.8 | -12.61 | -17.54 | -17.13 | -16.89 | -26.56 |
Interest Expense | -1.06 | -0.19 | -0.65 | -0.5 | -0.22 | -0.59 |
Interest & Investment Income | 0.72 | 0.8 | 0.53 | 0.02 | 0.03 | - |
Currency Exchange Gain (Loss) | -1.07 | 0.76 | -0.21 | 0.13 | -0.91 | -0.1 |
Other Non Operating Income (Expenses) | -0.13 | 0 | 2.68 | 5.65 | 17.13 | 0.35 |
EBT Excluding Unusual Items | -12.33 | -11.23 | -15.19 | -11.82 | -0.87 | -26.88 |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.12 | -0.5 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1.78 | 1.01 |
Asset Writedown | - | - | -9.7 | - | -17.57 | - |
Other Unusual Items | - | - | - | - | -0.8 | -0.14 |
Pretax Income | -12.33 | -11.23 | -24.9 | -11.82 | -17.58 | -26.52 |
Income Tax Expense | - | - | -0.38 | 0.08 | -1.52 | 0.13 |
Earnings From Continuing Operations | -12.33 | -11.23 | -24.52 | -11.9 | -16.06 | -26.65 |
Net Income | -12.33 | -11.23 | -24.52 | -11.9 | -16.06 | -26.65 |
Preferred Dividends & Other Adjustments | - | - | 0.64 | 8.52 | 4.99 | - |
Net Income to Common | -12.33 | -11.23 | -25.15 | -20.42 | -21.05 | -26.65 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 16 | 14 | 2 | - | - | - |
Shares Outstanding (Diluted) | 16 | 14 | 2 | - | - | - |
Shares Change | 92.11% | 794.77% | - | - | - | - |
EPS (Basic) | -0.79 | -0.78 | -15.65 | - | - | - |
EPS (Diluted) | -0.79 | -0.78 | -15.65 | - | - | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -13.78 | -14.83 | -17.65 | -12.75 | -16.84 | -14.89 |
Free Cash Flow Per Share | -0.88 | -1.03 | -10.98 | - | - | - |
Gross Margin | 100.00% | 100.00% | - | - | - | - |
Operating Margin | -3128.99% | -3939.06% | - | - | - | - |
Profit Margin | -3575.07% | -3509.69% | - | - | - | - |
Free Cash Flow Margin | -3994.78% | -4633.75% | - | - | - | - |
EBITDA | -10.8 | -12.6 | -17.53 | -17.09 | -16.83 | -26.45 |
D&A For EBITDA | -0.01 | 0.01 | 0.01 | 0.04 | 0.06 | 0.11 |
EBIT | -10.8 | -12.61 | -17.54 | -17.13 | -16.89 | -26.56 |
Revenue as Reported | 0.35 | 0.32 | - | - | - | - |